Provided by Tiger Trade Technology Pte. Ltd.

Cue Biopharma, Inc.

0.4859
-0.0424-8.03%
Volume:469.11K
Turnover:238.32K
Market Cap:38.26M
PE:-1.11
High:0.5399
Open:0.5239
Low:0.4810
Close:0.5283
52wk High:1.75
52wk Low:0.4810
Shares:78.74M
Float Shares:78.47M
Volume Ratio:2.78
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.7221
ROE:-195.19%
ROA:-62.31%
PB:2.89
PE(LYR):-0.67

Loading ...

Company Profile

Company Name:
Cue Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
41
Office Location:
40 Guest Street,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Frank Morich
Chairman
Usman Azam
President and Chief Executive Officer and Director
Jill Broadfoot
Director
Pamela Garzone
Director
Pasha Sarraf
Director
Patrick Verheyen
Director
Peter A. Kiener
Director

Shareholders

Name
Position
Usman Azam
President and Chief Executive Officer and Director
Colin G. Sandercock
Senior Vice President, General Counsel and Secretary
Daniel G. Baker
Interim Chief Development Officer
Lucinda Warren
Chief Business Officer